Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients

HIV Infections Clinical Trial

Official title:

Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00356616
• Other study ID #: TETRIZ
• Secondary ID: 2005-002203-17
• Status: Terminated
• Phase: Phase 4
• First received: July 24, 2006
• Last updated: January 25, 2008
• Start date: September 2005
• Est. completion date: June 2007

Study information

• Verified date: November 2007
• Source: Germans Trias i Pujol Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

To evaluate whether the combined therapy of two nucleosides plus one nucleotide (Trizivir + TDF) manages to keep CD4 lymphocytes stable in patients with HIV infection on antiretroviral treatment that present virological failure and multiple resistance to antiretrovirals.

Description:

This study has been designed to determine whether the use of a regimen based exclusively on NTRI, containing tenofovir, zidovudine and lamivudine, is able to preserve immunological status in patients with detectable viral load for whom an efficacious salvage regimen cannot be designed, slowing the progression of the viral load and reducing antiretroviral treatment-associated toxicity. In order to complete the salvage regimen without increasing the number of tablets too much, Trizivir plus tenofovir as investigational treatment will be used.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: June 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age>= 18 years.

2. HIV-1 infected patients.

3. Patients on antiretroviral treatment including NTRI + PI +/- NNRTI +/- fusion inhibitors at inclusion in the study.

4. Virological failure, defined as 2 determinations with viral load >1,000 copies/mL in the last 6 months, during stable HAART therapy over the previous 6 months.

5. Genotype or phenotype resistance to three families of antiretrovirals (PI, NTRI and NNRTI) demonstrated in genotype study carried out in the last 48 weeks and defined as:

• 3 or more TAMS of the following: M41L, E44D, D67N, V118I, L210W, T215Y/F, K219Q/E.

• Existence of the M184V mutation or probable presence in the cellular archives.

• 5 or more mutations that confer resistance to PI of the following: I10F/I/R/V, V32I, M46I/L, I54V/M/L, V82A/F/T/S/V, I84V/A/C, L90M.

• Existence of 1 or more mutations that confer resistance to NNRTI, or probable presence in the cellular archives of: K103N, Y181C/I/Y, G190S/A/G.

6. CD4 lymphocytes >- 300 cells/mm3 in the last two determinations.

7. Subject able to follow the treatment period.

8. Acceptance of the study and signature of the informed consent form.

9. Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study.

Exclusion Criteria:

• Suspicion of previous incorrect adherence.

• Pregnancy or breastfeeding

• Suspicion of intolerance to any investigational drug.

• Record of any disease which, according to clinical criteria, may reoccur with the proposed change of therapy (sarcoma, lymphoma, etc).

• CD4 Nadir below 200 cel/mm3.

• Acute intercurrent disease or fever in the 15 days before inclusion.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Trizivir (AZT+3HT+Abacavir) twice daily
Trizivir (AZT+3HT+Abacavir) twice daily
• Viread (300 mg Tenofovir disoproxil fumarate) once daily
Viread (300 mg Tenofovir disoproxil fumarate) once daily

Locations

Country	Name	City	State
Spain	H.U. Germans Trias i Pujol	Badalona	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Germans Trias i Pujol Hospital	Fundacio Lluita Contra la SIDA

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variations in the immune status of patients in each group throughout follow-up.		48 weeks	No
Secondary	Percentage of patients that increase viral load by > 0.5 log		weeks 12, 24, 36 and 48	No
Secondary	Percentage of patients that increase viral load by > 100,000 copies/mL		weeks 12, 24, 36 and 48	No
Secondary	Percentage of patients that present some clinical event, B or C classification according to the CDC.		during the 48 weeks of follow-up	Yes
Secondary	Percentage of patients that present clinical or analytical adverse effects degree > 2 according to the WHO classification.		weeks 12, 24, 36 and 48	Yes
Secondary	Percentage of patients that drop out of treatment.		weeks 12, 24, 36 and 48	Yes
Secondary	Percentage of patients that drop out of the study due to intolerance or adverse effects.		weeks 12, 24, 36 and 48	Yes
Secondary	Percentage of change in lipid determinations.		weeks 12, 24, 36 and 48 with regard to baseline	Yes
Secondary	Percentage of patients that report changes, improvement or worsening in redistribution of body fat.		weeks 12, 24, 36 and 48	No
Secondary	Percentage of patients that present adherence to the antiretroviral treatment > 95%.		weeks 12, 24, 36 and 48	No
Secondary	Percentage of patients that present improvement in the quality of life (MOS-HIV) and satisfaction questionnaires.		weeks 12, 24, 36 and 48	No
Secondary	Percentage of patients that present an increase in the number of active drugs.		at the end of the study	No